Indegene

Hyderabad, you brought the energy 🔥 Echoing the Bengaluru and Pune editions, our first Connect & Celebrate in the city revisited Indegene's 27 years of future-ready innovation: milestone builds that moved the work, AI in day-to-day use making it faster and safer, and the plans that take us forward. Proud of the momentum, excited for the road ahead! #FutureReadyCareers

MFN discussions are resurfacing — and they could influence how pricing evolves across major markets. At the recent Indegene Digital Summit 2025 (Virtual Edition) panel discussion, leaders Bill Lobb, Dr. med. Harald Herholz, MPH Jeff Dunn James Mahon and Nekshan Dalal, noted a consistent theme: the gap between list price and actual net price continues to widen. That gap affects affordability, access, and the long-term sustainability of innovation. Global reference pricing, confidential discounts, and varying purchasing models mean stakeholders often work with different signals. Drug prices have doubled every 4 years in the U.S., while confidential discounts in some markets reach 80–90%. Programs like 340B add further layers that shape how value moves through the system. No single stakeholder created this complexity — but it now shapes how price, value, and access intersect. Leaders at the Summit emphasized the need for clearer alignment: 🟢 Transparency in how value is recognized 🟢 Flexible, outcomes-aligned contracting models 🟢 Mechanisms that support both patient access and predictable incentives for R&D These aren’t quick fixes, but they offer a more stable path than isolated policy shifts. The direction of MFN may matter less than how effectively the ecosystem aligns around shared outcomes. For a deeper perspective from experts across the U.S., UK, and Germany, the full discussion in the blog offers helpful context. #PractitionerLevelConfidence

With GenAI moving fast, what’s slowing down real outcomes?   Pharma is investing aggressively in GenAI and digital platforms, yet most outcomes stall at the pilot stage. The barrier isn’t the technology. The barrier is choosing the right use cases, designing for scale, and building the operating model that can support them.   At the Indegene Digital Summit 2025, industry leaders outlined what must shift before organizations can unlock real, sustained impact:   🟢 Stop proving the tech works. Start proving it matters → Many pilots succeed, but few translate into sustained outcomes. Real value comes from use cases that directly support business and patient priorities. 🟢 Let strategy lead every technology decision → Digital and AI only create impact when rooted in commercial, clinical and patient agendas. Without that anchor, they operate as side projects instead of engines for growth. 🟢 Fix the structural friction that slows progress → Innovation rarely fails at the technical layer. It fails in governance, slow decision-making and fragmented accountability. 🟢 Use contained markets to pressure-test real scalability → Running a single country end to end reveals the true blockers to enterprise rollout — data quality, compliance maturity, cross-functional alignment — long before they multiply globally. 🟢 Empower cross-functional ownership → Technology delivers impact when someone owns the mission from start to finish. Unified accountability removes hierarchy and turns intentions into outcomes. 🟢 Adopt a flexible, learning-driven operating model → Transformation requires iteration, adaptation and rapid adjustment as new data and realities emerge. 🟢 Invest in the human side of change → People adopt what they understand and feel part of. Transformation accelerates when teams feel informed, included and confident in the direction.   Technology creates measurable outcomes only when organizations simplify, align and empower the system around it.   Where do you think digital transformation breaks down most often? Drop your thoughts below. #PractitionerLevelConfidence

𝐖𝐡𝐚𝐭 “𝐑𝐞𝐚𝐥-𝐓𝐢𝐦𝐞” 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐑𝐞𝐚𝐥𝐥𝐲 𝐌𝐞𝐚𝐧𝐬 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥   In today’s commercial environment, decisions must be sharper, faster, and anchored in data, especially as budgets tighten, engagement time with HCPs and patients narrows, and competition within therapeutic areas intensifies. Yet even with rapidly expanding datasets across claims, genomics, EMRs, labs, and digital engagement, real-time intelligence often remains out of reach.   A clear message for leaders emerged at Indegene Digital Summit (IDS) 2025 from Arnaub Chatterjee meaningful progress begins with fixing foundational barriers. Data across clinical, commercial, and medical functions continues to sit in silos; AI outputs depend heavily on data quality; procurement cycles remain long and expensive; and organizations are shifting toward fit-for-purpose data after seeing limited ROI from broad syndicated datasets.   To move toward real-time decision-making: 🔹 Establish a tokenized data layer to securely connect first-party and external datasets without exposing PII, enabling cleaner information and continuous patient-level visibility from trial consent through post-launch. 🔹 Redesign procurement for speed and measurable ROI, focused on datasets aligned to specific commercial questions and shorter validation cycles. 🔹 Activate tokenized data within CRM and ad-tech ecosystems like LiveRamp, DeepIntent, Swoop, and Veeva to build precise, behavior-aligned audience segments. 🔹 Strengthen data quality and interoperability, leveraging automation and emerging LLM-enabled cleanup to make data more turnkey for commercial use.   The takeaway for leaders: tokenization is commercially mature and in active use — organizational readiness is now the key differentiator. #PractitionerLevelConfidence

The 44th Annual J.P. Morgan Healthcare Conference is where the most influential voices in healthcare, biotech, and investment converge. Our team will be in San Francisco throughout JPM Week, connecting with peers on the forces that will shape impact in 2026 and beyond.   We’re excited and looking forward to meaningful conversations! Meet us there: https://lnkd.in/dbsWRgey Sanjay Parikh, Gaurav Kapoor, Gobin Chandra, Paresh Rajpurohit #PractitionerLevelConfidence

We are excited to be recognised among the Best Companies for Women in India with a Hall of Fame distinction 🏆 by Avtar - Leaders in Workplace Culture & Inclusion and Seramount yet again! We’re super-proud of our women employees 👭 and committed to fostering a diverse, inclusive workplace where they can thrive. #FutureReadyCareers

When does “more omnichannel” actually mean less progress?   Pharma’s omnichannel ambition has never been higher, yet the path to real impact keeps slowing down. Even with richer data, smarter engines, and more activation routes than ever, organizations still struggle to turn effort into momentum. The issue is not intent. The issue is the interference that builds up around it.   At the Indegene Digital Summit 2025, leaders aligned on a clear conclusion: omnichannel will not advance by adding more. It will advance by removing what creates drag and keeps teams from moving at the speed healthcare demands.   The organizations gaining ground are already making this shift: 🟢 Focusing on fewer high value omnichannel plays that scale across brands 🟢 Consolidating capabilities that were previously scattered across multiple platforms 🟢 Standardizing omnichannel templates, taxonomies and workflows to boost delivery speed by up to 50 percent 🟢 Clearing out operational friction so decisions move faster and optimization becomes continuous   A new omnichannel model is taking shape. It is built on leaner foundations, tighter integration and teams that operate at an orchestrator level. When organizations remove what slows them down, omnichannel becomes what it was always meant to be: precise, agile, adaptive and aligned with real HCP behavior.   Which part of omnichannel needs simplification the most? Add your insights in the comments. #PractitionerLevelConfidence

The future of MLR will be shaped by how well humans and AI work together. Our latest whitepaper, developed in collaboration with experts Georgia Gayle, Narmada Rosner, MBA, MSc, Radha Nair and Mohit Jain , explores how human expertise and AI capabilities can work together to strengthen the review process, accelerating content delivery, and transforming MLR into a more agile and scalable function. It offers practical guidance on where AI adds value, where human oversight remains essential, and how cross-functional teams can build the right governance, trust, and readiness for enterprise adoption. If you want a glimpse into how the industry is preparing for the next era of MLR, this is a must-read. Human plus AI is the path forward. https://lnkd.in/d_k-AaK5 #PractitionerLevelConfidence

AI race in pharma won’t be won by bold visions — it will be won by 𝐑𝐄𝐀𝐃𝐈𝐍𝐄𝐒𝐒 𝐭𝐨 𝐚𝐜𝐭. AI acceleration curve is shifting fast, yet many organizations still rely on fragmented data, rigid governance, and long planning cycles that simply can’t keep pace. Here’s what it takes to lead the industry: → Clean, connected data—not flashy tools → Short, iterative cycles beat multi-year roadmaps → Co-creation with IT replaces “throw it over the fence” → IT evolves from gatekeeper to strategic partner → Empowered teams make smarter, faster, “safe-to-try” decisions Why does this matter now? Because AI value shows up in weeks and months, not in distant strategy roadmaps. Because AI readiness isn’t a technical milestone—it’s an organizational mindset. Because every experiment, even imperfect ones, accelerates enterprise learning. The shift is clear: AI becomes impactful when leaders enable teams closest to the work to act with context, collaborate across boundaries, and focus relentlessly on measurable value rather than hype. The companies who move from planning to doing will outpace those still searching for the “perfect” strategy. What’s stopping most organizations? Not capability. Not vision. It’s action. Is your AI strategy built for real motion? Share one shift that would help your organization move from planning to doing. #PractitionerLevelConfidence

AI in healthcare doesn’t fail because the models are weak. It falls short when interactions break down.   In our new report, Vinod Gowda and Rishabh Nadkarni explore why life sciences teams need a more deliberate, human-centered approach to AI, and how clear human-AI interaction guidelines can make systems more intuitive and easier to trust.   Read the full report here: https://lnkd.in/dJVP-nA3 #PractitionerLevelConfidence